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Biomaterials used as matrix for dissolving microneedles (dMNs) may affect the 
manufacturing process as well as the potency of the active pharmaceutical ingredient, e.g. the 
immunogenicity of incorporated vaccine antigens. The aim of this study was to investigate the 
effect of the molecular weight of hyaluronan, a polymer widely used in the fabrication of 
dMNs, ranging in molecular weight from 4.8 kDa to 1.8 MDa, on the dissolution of 
microneedles in the skin in time as well as the antibody response in mice and T-cell activation 
in vitro. Hyaluronan molecular weight (HA-MWs) did not affect antibody responses (when 
lower than 150 kDa) nor CD4+ T-cell responses against model antigen ovalbumin. However, 
the HA-MWs had an effect on the fabrication of dMNs. The 1.8 MDa HA was not suitable for 
the fabrication of dMNs. Similarly, the 4.8 kDa HA generated dMN arrays less robust 
compared to the other HA-MWs requiring optimization of the drying conditions. Finally, 
higher HA-MWs led to longer application time of dMN arrays for a complete dissolution of 
microneedles into the skin. Specifically, we identified 20 kDa HA as the optimal HA-MW for 
the fabrication of dMNs as with this MW the dMNs are robust and dissolve fast in the skin 
without affecting immunogenicity. 
 
Keywords 




Microneedles are intensively studied for dermal and transdermal drug and vaccine delivery (1, 
2). Microneedles are needle-like structures up to 1 mm in length, capable of piercing the 
upper layer of the skin, the stratum corneum, enabling drug and vaccine delivery in a 
minimally invasive and painless way (3, 4). Several microneedle concept are in development: 
i) hollow microneedles to inject liquid formulations through the bore of the microneedle, ii) 
microneedles for skin pretreatment to create microchannels prior application of a patch 
containing the drug or vaccine formulation, iii) porous, coated, hydrogel-forming 
microneedles and dissolving microneedles that release the drug or vaccine upon insertion into 
the skin (5-8). Dissolving microneedles (dMNs), completely dissolve after insertion into the 
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skin, thereby releasing the encapsulated drug or vaccine (3). As an additional advantage, the 
dry state of dMNs combined with the presence of excipients can increase protein 
thermostability (3). 
dMNs are produced from different materials, ranging from low molecular weight 
carbohydrates to biodegradable polymers (3). The selection of the matrix material is based on 
different factors such as i) safety, ii) compatibility with the active compound and the 
manufacturing procedure, iii) capability of the manufactured dMNs to efficiently pierce the 
skin and subsequently dissolve in a short time period and iv) potential adjuvant properties. 
One of the most frequently used matrix material is the hyaluronan (HA) (3, 9-13). High 
molecular weight HA is a non-toxic, biodegradable, biocompatible and non-inflammatory 
linear polysaccharide (14) naturally present in the skin and approved by the FDA as inactive 
material. 
Although frequently used for microneedle manufacturing, the molecular weight of the 
polysaccharide HA is rarely addressed (1, 3, 9, 11, 12, 15-17). There are indications however, 
that the molecular weight of the HA influences its immuno-adjuvant properties. Only high 
molecular weight HA (HMW-HA, MW 107 Da) is an ubiquitous extracellular matrix 
component (18, 19). Low molecular weight HA (LMW-HA) (4- to 16-oligosaccharide size, 
800 – 3200 Da (19, 20)) is able to activate immunocompetent cells such as macrophages (21) 
and DCs (19-23). These activated human DCs are able to stimulate T-cell mediated immune 
responses (19, 20, 24). The immune activation is mediated by the HA binding to specific 
receptors such as CD44, CD168, Toll-like receptor (TLR)-2 and TLR-4 (25-28). The latter is 
a receptor associated with the innate immunity and the host defence against bacterial infection 
(20). In the presence of antigens, a specific response may develop (29) and so the LMW-HA 
can act as an adjuvant during vaccination. 
In a previous study from our group, the dissolving microneedle properties of the only 150 kDa 
HA, such as penetration and dissolution in the skin, have been reported (30). 
The aim of this study was to determine whether i) HA with different MW had an effect on the 
immune response for both antibody (in vivo injections by hMN) and cellular (in vitro T-cell 
exposure) responses and ii) it was possible to fabricate dMNs by micromolding from HA with 
different molecular weight. To this end, first the potential adjuvant effect of HA was assessed 
by i) performing immunization studies investigating the antibody response in mice injected 
with the model antigen ovalbumin (OVA) in presence of a range of different HA-MWs and ii) 
investigating T-cell activation in vitro upon exposure to several HA-MWs with OVA. 
Subsequently, different HA-MWs were used to fabricate dMNs assessing the compatibility of 
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the matrix material of each MW with the manufacturing procedure. These dMNs were used to 
investigate their capability to pierce the skin and to dissolve in reasonable short time period. 
 
2. Materials and methods 
2.1 Materials 
Hyaluronan (HA) (sodium hyaluronate, average Mw was 4.8 kDa, 20 kDa and 150 kDa 
(endotoxin level ≤ 0.05 EU/mg) or 1.8 MDa (endotoxin level ≤0.07 EU/mg)) was purchased 
from Lifecore Biomedical (Chaska, MN, USA). Immunization studies, ELISA and cell 
culturing were performed by using endotoxin-free ovalbumin (OVA) (endotoxin level < 1 
EU/mg) from Invivogen (Toulouse, France). PBS pH 7.4 for hMN injections was obtained 
from B. Braun, Melsungen, Germany. 
 
For cell culture, Ca2+- and Mg2+-free phosphate-buffered saline (PBS), Iscove's Modified 
Dulbecco's Medium (IMDM), Roswell Park Memorial Institute Medium (RPMI 1640), 
penicillin/streptomycin and l-glutamine were purchased from Lonza (Basel, Switzerland). 
Fetal calf serum (FCS) and granulocyte-macrophage colony-stimulating factor (GM-CSF) 
were purchased from GE Healthcare (Little Chalfont, UK) and PeptroTech (London, UK) 
respectively. Lipopolysaccharide (LPS) extracted from Salmonella typhosa, CFSE and β-
mercaptoethanol were purchased from Sigma-Aldrich (Zwijndrecht, the Netherlands). 
The antibodies CD25-APC (PC 61.5), CD69-PE (H1.2F3), Thy1.2-PE-Cy7 (53–2.1), CD4-
eFluor450 (GK1.5), Vα2 TCR-PE (B20.1) and fixable viability dye-eFluor780 were 
purchased from eBioscience (Thermofisher Scientific, MA, USA). 
 
For dissolving microneedle fabrication, 10 mM PB (7.7 mM Na2HPO4, 2.3 mM NaH2PO4, pH 
7.4) was prepared in the laboratory. Vinylpolysiloxanes A-silicone (Elite Double 32a Normal) 
and the two-component epoxy glue (Bison, Goes, The Netherlands) were obtained from The 
Zhermack Group (Badia Polesine, Italy) and Bison International B.V. (Goes, The 
Netherlands), respectively. Polydimethylsiloxane (PDMS, Sylgard 184) was purchased from 
Dow Corning (Midland, MI, USA). Solid silicon MNs, obtained through a potassium 
hydroxide wet-etching process (31), were kindly provided by the Tyndall National Institute 
(Cork, Ireland). All the chemicals were of analytical grade and Milli-Q water (18 MΩ/cm, 
Millipore Co.) was used for the preparation of all solutions. 





Immunization studies were performed using female BALB/c (H2d), 8-11 weeks old (Charles 
River, Maastricht, The Netherlands) and randomly assigned to groups of 8. The studies were 
approved by the ethical committee on animal experiments of Leiden University (License 
number (14176). 
For in vitro T-cell activation studies, C57BL/6 and OT-II transgenic mice on a C57BL/6 
background were purchased from Jackson Laboratory (CA, USA), bred in-house under 
standard laboratory conditions, and provided with food and water ad libitum. All animal work 
was performed in compliance with the Dutch government guidelines and the Directive 
2010/63/EU of the European Parliament. Experiments were approved by the Ethics 
Committee for Animal Experiments of Leiden University (CCD number 
AVD106002017887). 
 
2.3 Hollow microneedles 
Hollow microneedles (hMNs) were prepared as described previously (32, 33) (a 
representative image of a hMN is reported in the Supplementary data, Figure S1). Briefly, 
polyimide-coated fused silica capillaries (Polymicro, Phoenix AZ, 375 μm outer diameter, 50 
μm inner diameter) were filled with silicone oil in a vacuum oven (100 °C) overnight. 
Subsequently, the capillaries were etched during 4 h in ≥ 48% hydrofluoric acid and the 
polyimide coating was removed from the ends of the capillaries by diving them into heated 
(250 °C) sulfuric acid for 5 min. 
 
2.4 Immunization studies 
BALB/c mice were anesthetized by intraperitoneal injection of 150 mg/kg ketamine and 10 
mg/kg xylazine and the injection site was shaved (approximately 4 cm2). The same day, mice 
were immunized by intradermal hMN injection (120 µm injection depth) of 10 µl with 0.31 
µg OVA with 3.1 µg HA for each HA-MW dissolved in PBS pH 7.4. Intradermal hMN 
injection of each HA-MWs without OVA and PBS were included as control. For controlled 
depth intradermal microinjections, a hollow-microneedle applicator was used as reported 
previously (32). 
Immunizations were performed at day 1 (prime), day 22 (boost) and day 43 (2nd boost). Prior 
to each immunization, a blood sample was collected from the tail vein. At day 63, the blood 
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sample was collected from the femoral artery and all mice were sacrificed. Serum was 
isolated from the samples and stored at - 80°C. 
 
2.5 Determination of OVA-specific IgG antibodies 
OVA-specific antibodies were analysed by a sandwich enzyme-linked immunosorbent assay 
(ELISA) as described earlier (10). Briefly, well-plates were coated with OVA for 1.5 h at 37 
°C and then blocked with bovine serum albumin (BSA) (Sigma-Aldrich, Zwijndrecht, the 
Netherlands). After the blocking, three-fold serial dilutions of serum were applied to the 
plates and incubated for 1.5 h at 37 °C. Then, the plates were incubated with horseradish 
peroxidase-conjugated goat antibodies against IgG total, IgG1 and IgG2a (Southern Biotech, 
Birmingham, AL, USA) for 1 h at 37 °C. Finally, 1-step TM ultra 3,3′,5,5′-
tetramethylbenzidine (TMB) (Thermo-Fischer Scientific, Waltham, USA) was used as 
substrate and sulfuric acid (H2SO4) (95–98%) (JT Baker, Deventer, The Netherlands) was 
added to stop the reaction. The absorbance was measured at 450 nm on a Tecan Infinite 
M1000 plate reader (Männedorf, Switzerland) and the antibody titers were determined as the 
log10 value of the mid-point dilution of a complete s-shaped absorbance-log dilution curve of 
the diluted serum level. 
 
2.6 Bone marrow-derived dendritic cells (BMDCs) 
To examine T-cell activation in vitro, first bone marrow was isolated from the tibias and 
femurs of C57BL/6 female mouse. A single-cell suspension of bone marrow cells was 
obtained by using a 70 μm cell strainer (Greiner Bio-One B.V., Alphen aan den Rijn, NL). 
The cells were cultured in IMDM medium supplemented with 2 mM  l-glutamine, 8% (v/v) 
FCS, 100 U/mL penicillin/streptomycin and 50 μM β-mercaptoethanol at 37 °C and 5% CO2 
in 95 mm Petri dishes (Greiner Bio-One B.V., Alphen aan den Rijn, NL) and 20 ng/mL GM-
CSF for 10 days. Medium was refreshed every other day. 
On day 11, the BMDCs were harvested from the petri dish and distributed into 96-well plates 
(100 µl/well, 10 000 cells/well). Then, 100 µl/well of formulations consisting of: i) 5 µg 
OVA, ii) 5 µg OVA mixed with 50 µg HA (per each molecular weight) or iii) 50 µg HA (per 
each molecular weight) were added to the wells. OVA (5 µg/well) + LPS (100 ng/well) or 
LPS (100 ng-well) were added as positive control; medium was included as negative control. 
The BMDCs were exposed to the formulations overnight at 37 °C and 5% CO2 and 
subsequently OVA-specific CD4+ T-cells were transferred on BMDCs in co-culture 
experiments (see 2.6). 




2.7 CD4+ T-cell activation by antigen loaded BMDC 
OT-II (OVA-specific CD4+) T-cells were obtained from the spleen of OT-II transgenic 
C57BL/6 mouse. Single cell suspensions were obtained by forcing the spleens through a 70 
µm strainer. After erythrocyte depletion with lysis-buffer (0.15 M NH4Cl, 1 mM KHCO3, 
0.1 mM Na2EDTA; pH 7.3), staining with CFSE was performed. Briefly, cells were 
suspended in PBS containing 1 μM CFSE and incubate 10 min at room temperature. CFSE 
was neutralized by FCS addition and the cells were washed with RPMI to remove excess of 
CFSE. 
At this point, the percentage of CD4+/Valpha2+ cells was determined by flow cytometry (BD 
FACSCanto-II, San Jose, CA). OT-II cells were transferred on BMDCs previously exposed to 
the formulations (50 000 cells/well). 
On day 15, the cell surfaces were stained by incubating the cells with fixable viability dye-
eFluor780 (1:1000) and fluorescently labelled antibodies specific for: Thy1.2-PE-Cy7 
(1:500), CD25-APC (1:500), CD69-PE (1:500) and CD4-eFluor450 (1:500) for 30 min (100 
μl/well) at 4 °C. After 30 min, the excess antibodies were washed by using FACS buffer. The 
cells were incubated with fixation and permeabilization solution (BD Biosciences) for 10 min 
at 4 °C. Finally, the cells were washed with FACS buffer and analysed by flow cytometry 
(BD FACSCanto-II, San Jose, CA). The data were analysed by using FlowJo software. 
 
2.8 Fabrication of dissolving microneedles 
dMN arrays were prepared as described previously (10). HA 10% (w/v) was dissolved in 
phosphate buffer (10 mM, pH 7.4) and stored overnight. The next day, HA solution was 
poured in each well of the polydimethylsiloxane mold (PDMS, Sylgard 184, Dow Corning, 
Midland, MI, USA) to prepare dMN arrays (4 by 4 dMNs per array of 300 µm length and 100 
µm base diameter). After several steps of vacuum and centrifuge, the 20 kDa and 150 kDa 
HA arrays were oven-dried overnight at 37°C. As this procedure result in fragile dMN arrays 
when using 4.8 kDa HA, these dMN arrays were dried at room temperature overnight. The 
next day, a backplate was produced by pouring a mixture of vinylpolysiloxane base and 
catalyst (in a 1:1 ratio) (Elite Double 32a Normal, Zhermack Group, Badia Polesine, Italy) 
and subsequently a two-component glue solution (Bison International B.V., Goes, The 
Netherlands) onto each array and left curing. 
Finally, the arrays were removed from the PDMS mold and inspected for shape and sharpness 
by light microscopy (Stemi 2000-C, Carl Zeiss Microscopy GmbH, Göttingen, Germany). 




2.9 Human skin 
Human abdomen skin was obtained from a local hospital within 24 hours after cosmetic 
surgery according to the declaration of Helsinki. The fat excess was removed with a scalpel 
and the skin was stored at -80°C. Before use, the skin was thawed at 37°C for 1 h in a humid 
petri dish and stretched with pins on parafilm-covered styrofoam. Before starting the 
experiment, the skin was cleaned with Milli-Q and 70% ethanol. 
 
2.10 Penetration of microneedles in ex vivo human skin  
dMN arrays (n=3 per HA-MW) were applied onto the skin by impact velocity, as described 
elsewhere (10, 34), by using an impact insertion applicator with a constant velocity of 0.54 
m/s (Leiden University - applicator with uPRAX controller version 0.3). The dMNs were kept 
in the skin for 18 seconds and withdrawn. Then, the pierced skin was treated with trypan blue, 
as previously described (35) and stratum corneum was removed by tape stripping. Finally, the 
blue spots were visualized using a light microscope (Axioskop and Stemi 2000-C, Carl Zeiss 
Microscopy GmbH, Göttingen, Germany) (a representative image of pierced skin is reported 
in the Supplementary data, Figure S2) and the penetration efficiency per array was calculated 
by dividing the number of blue spots by the number of dMNs on the array (16) (Equation 1). 
 
             Penetration efficiency =
number of blue spots
16
 x 100               (Eqn. 1) 
 
2.11 Dissolution of microneedles in ex vivo human skin  
A dMN array (n=7) was applied on the skin as described in section 2.10 and was kept in the 
skin for 1 min, 5 min, 10 min or 20 min. The microneedle length before and after dissolution 
was determined with a light microscope (Axioskop and Stemi 2000-C, Carl Zeiss Microscopy 
GmbH, Göttingen, Germany) equipped with a digital camera (Axiocam ICc 5, Carl Zeiss). In 
order to obtain the dMN dissolved volume for each insertion period, dissolved microneedle 
length was measured by ZEN 2012 blue edition software (Carl Zeiss Microscopy GmbH) and 
the dissolved MN volumes were calculated as reported in our previous study in supplementary 
Figure 3 (10). 
 
2.12 Statistics 
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IgG titers and T-cell response were analysed using one-way ANOVA with respectively 
Bonferroni and Tukey’s post-test suitable in the software Prism (Graphpad, San Diego, USA). 
A p-value less than 0.05 was considered to be significant. 
Microneedle penetration efficiency was analysed by Kruskal-Wallis test with Dunn's multiple 
comparison test (p < 0.05). 
The remaining dMN length after dissolution at different time points was analysed by two-way 




3.1 Immunization studies 
The liquid formulations of OVA alone or mixed with different HA-MWs was intradermally 
injected by using hollow microneedles. During injection no problems with clogging or 
leakage were observed. The formation of a blister on the site of the injection indicated a 
successful intradermal delivery of the formulation. No adverse effects were observed. 
The OVA-specific total IgG titers increased after each immunization (Figure 1A-C). The 
presence of HA, regardless of the molecular weight, did not increase the total IgG response 
compared to the injection of OVA only. After the first boost, a higher OVA specific IgG 
response in the mice immunized with OVA-HA 4.8 kDa was observed compared to the mice 
injected with OVA-HA 150 kDa (p<0.01). However, both OVA-HA 4.8 kDa and OVA-HA 
1.8 MDa resulted in equal responses compared to the OVA only group. After the second 
boost, the group immunized with OVA-HA 1.8 MDa showed lower OVA-specific total IgG 
titers than OVA only and OVA-HA 4.8 kDa, suggesting a detrimental effect on adding high 
molecular weight HA. Overall, the presence of high MW HA seemed to reduce the 
immunogenicity of the antigen while the presence of HAregardless of the molecular weight 
did not enhance the immune response compared with OVA alone. 
The IgG1 response (Figure 1 D-F) followed the same trend as the total IgG response: the 
presence of HA in different molecular weights did not change the response compared to OVA 
alone after each immunization. Intradermal injection of OVA, with or without HA, resulted in 
undetectable OVA specific IgG2a responses (data not shown). 




Figure 1. OVA-specific IgG total (A-C) and IgG1 (D-F) antibody titers measured in 
BALB/c mice on day 21 (A and D), day 42 (B and E) and day 63 (C and F). Bars 
represent mean ± SEM, n = 8. *p < 0.05, **p < 0.01. OVA: ovalbumin; HA: hyaluronan. 
 
3.2 Analysis of CD4+ T-cell activation in vitro 
To determine whether the presence of different HA-MW, with or without OVA, affect celllar 
responses, OT-II T-cell (OVA-specific CD4+ cells) activation studies were performed in vitro. 
As expected, addition of OVA induces OT-II proliferation, which is enhanced in the presence 
of LPS (Figure 2). The co-exposure of cells to OVA and HA however, regardless of the 
molecular weight, did not increase OT-II proliferation compared to OVA alone. In line with 
the antibody responses, this suggests that none of the tested HA polymer provided a 
measurable adjuvant effect. 




Figure 2. OT-II activation in vitro. (A) percentage of dividing cells, (B) percentage of 
CD69+/CD25+ cells. Bars represent mean ± SEM, n = 3. *p < 0.05, **p < 0.01. OVA: 
ovalbumin; HA: hyaluronan; LPS: lipopolysaccharide; s.d.: significantly different. 
 
3.3 Dissolving microneedle fabrication 
The immunological analysis of the various HA polymers, suggests a preference for small MW 
polymer, as the high MW polymer show reduced antibody titers. Next we determined whether 
the MW of HA affected the fabrication of dissolving microneedles and their dissolution in the 
skin. Fabrication of dissolving microneedles was possible for the HA-MWs 150 kDa, 20 kDa 
and 4.8 kDa. The 10% (w/v) concentration of MW 1.8 MDa HA led to gel formation 
preventing the fabrication of microneedles. For the HA-MW 4.8 kDa, the fabrication of 
dissolving microneedles with a final step of drying at 37°C, as performed for the 150 kDa and 
20 kDa HA, led to ruptures on the microneedle arrays surface (data not shown). Thus, the 
drying was performed at room temperature, resulting in intact microneedle arrays. 
 
3.4 Penetration and dissolution of microneedles in ex vivo human skin 
In order to assess whether the molecular weight of HA had an effect on the capability of 
microneedles to pierce and dissolve into the skin, first their ability to pierce ex vivo human 
skin was tested. Bright field analysis showed sharp microneedles regardless of the HA-MW 
(Figure 3A).The penetration efficiency of microneedles into the skin was not affected by the 
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molecular weight of the HA. The 150 kDa microneedles showed a penetration efficiency of 
96 ± 7%; 20 kDa and 4.8 kDa HA microneedles showed a penetration efficiency of 98 ± 4%, 
(mean ± SD, n=3). 
Dissolution studies showed a gradual dissolution in time irrespective of the HA-MW (Figure 
3A). However, while 20 kDa and 4.8 kDa HA dMNs completely dissolved within 20 minutes 
application in the skin (9 7± 2% and 100 ± 0% dissolved volumes respectively), the 150 kDa 
HA dMNs reached only 80% dissolved volume after the same application time (Figure 3A). 
No differences in dissolved volumes between 20 kDa and 4.8 kDa HA microneedles at each 
application time were observed (Figure 3B), however the dissolved volume of the 150 kDa 
HA microneedles was significantly reduced at each time point compared to the other HA-MW 
microneedles. This resulted in a complete dissolution of the 20 kDa and 4.8 kDa HA 
microneedles after 10 minutes application, while the 150 kDa HA microneedles took 20 
minutes to almost completely dissolve. 




Figure 3. dMN dissolution in ex vivo human skin. A) Representative bright field images (5x) 
of 10% (w/v) HA 4.8 kDa, 20 kDa and 150 kDa microneedle before application on the skin (0 
min) and after 1, 5, 10 and 20 min dissolution in ex vivo human skin. Dissolved volumes are 
reported as mean ± SEM (n = 7). Scale bar 100 µm. B) Effect of time (1, 5, 10 and 20 min) on 
dissolution per each HA-MW dMN type (statistics in black) and effect of HA-MWs on 
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dissolution of dMNs at different time points (red statistics) are shown. Significance 
(**p<0.01, **p<0.001 and ****p < 0.0001) was determined by a two-way ANOVA with a 
Tukey’s post-test (n = 7). All data are presented as mean ± SEM. HA: hyaluronan. 
 
4 Discussion 
When choosing the HA polymer for the fabrication of dMNs, it is relevant to investigate 
potential immune modulating effects besides effects related to the dMN manufacturing and 
physicochemical characteristics of dMNs such as capability to pierce the skin and dissolve 
quickly. 
 
Although LMW-HA can have inflammatory properties in contrast to HMW-HA (19, 20, 22, 
36, 37), to our knowledge, the role of HA-MW on the antibody response has not been 
reported yet. To this end, in the present study HA ranging from 4.8 kDa to 1.8 MDa mixed 
with OVA was injected intradermally in mice to assess the antibody response evoked. We did 
not observe an increase in antibody titers by adjuvanting with LMW-HA; however we did 
observe that HMW-HA (1.8 MDa) reduced the antibody level after the second boost 
compared to OVA only and LMW-HA 4.8 kDa HA mixed with OVA. This may be explained 
by reports that HMW-HA exerts an anti-inflammatory role reducing the side effects of 
vaccines (38, 39) and displays immunosuppressive properties (40-42). To this end, it has been 
reported that HMW-HA up-regulates the transcription factor FOXP3 on regulatory T-cells 
(Treg) (e.g. CD4+ CD25+) (42) involved in the regulatory mechanism of autoantibody 
production (43) and likely antibody production. Although we did not investigate Treg 
activation in this study, they provide a potential mechanism regarding the lack of 
immunogenicity of HMW-HA. 
The role of what in literature is defined as LMW-HA has been extensively investigated 
suggesting a pro-inflammatory effect in vitro: 4-6 oligosaccharides HA induced cytokine 
synthesis in dendritic cells (19, 20); HA < 250 kDa induced inflammatory cytokines levels 
(36, 44-48); HA ≤ 800 kDa led to activation of macrophages (37). In this study, the effect of 
HA-MW was examined on the activation of CD4+ T-cells. Although this is an in vitro system, 
it has shown to be predictive in the sense that formulations that induce strong in vitro 
response of OT-II cells also outperformed other formulations in vivo (49, 50). Conversely to 
what has been reported in literature, changes in HA-MW did not influence the proliferation 
and activation of CD4+ T-cells in vitro. Considerations justifying the referred controversial 
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effects of HA preparations may be related to i) MW of HA that is not always measured 
accurately or is not homogeneous in the same HA population, for this reason an effect may be 
attributed to a minor population, ii) the presence of minor contaminants even in highly 
purified HA and iii) the conformational diversity of HA highly dependent on pH, temperature, 
salt concentration and specific cations (48). Furthermore, the effects of HA-MW seems to be 
cell-specific and depending on the HA medium concentration (26, 48). However, in literature 
there is not an optimal HA concentration reported and often the same concentration of 
different HA-MWs may have opposite effects on CD4+ cellular response (42). This lack of 
data should be addressed in future investigations, i.e. i) HAs in a wide range of concentrations 
with a dose/response on specific cell types and ii) cytokines produced by DCs and CD4+ T-
cells after exposure to the HA formulations, to obtain additional information on the regulatory 
effect of HA. 
 
Due to the absence of intrinsic adjuvant properties of HA, regardless of the molecular weight, 
all the HA-MWs were tested for potential effects on the manufacturing of dMNs and their 
capability to penetrate the skin and quickly dissolve. As reported in literature, a factor 
influencing the dMN dissolution time in the skin is the HA concentration (10, 51). However, 
to our knowledge, the role of the HA-MW on the dMN dissolution in the skin is reported in 
the present study for the first time highlighting the novelty of this study. HA is being used in 
experimental drug delivery systems. The lack of immune activation of HA, regardless MW 
may be used to taylor drug release kinetics. However, although we did not show 
immunological effects, using low MW HA, may introduce safety concerns, since low MW 
fragments (oligomers) are associated with inflammatory responses (52). 
Difficulties or impossibility in dMN fabrication when choosing too low (4.8 kDa) or high (1.8 
MDa) HA-MWs, respectively, identified an optimal HA-MW in the middle range (20 kDa 
and 150 kDa). The 4.8 kDa HA could only be formulated into dMN by drying at room 
temperature to avoid ruptures of the dMN arrays. Although drying at low temperature (room 
temperature) can preserve the antigen stability, it may lead to long processing time not 
compatible with scalability in fabrication and to a higher residual moisture content in dMN 
than drying at high temperature, potentially resulting in decrease in antigen stability. The HA-
MW 1.8 MDa formed a gel, due to the high viscosity, preventing further processing into 
dMNs. Furthermore, increase in HA-MW led to prolonged application time for a complete 
dMN dissolution into the skin. 
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Based on the result described above, the 20 kDa HA should be preferred to the 4.8 kDa and 




The present study underlines the importance of defining a specific HA-MW for the fabrication 
of dMNs based on the investigation and assessment of the effects of the HA-MW on the 
immune response and on the physicochemical characteristics of dMNs such as capability to 
pierce the skin and dissolve quickly. 
We consider, among the HA-MWs investigated, the medium-low HA-MW of 20 kDa the 
optimal MW as it results in robust dMNs characterized by a fast dissolving process in the skin 
and has no effect on the immunogenicity of the antigen. 
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